

SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

Kimberly A. Kraynyak, PhD^{1*}, Elliott Blackwood, MS^{1*}, Joseph Agnes, PhD^{1*}, Pablo Tebas, MD³, Mary Giffear, BS¹, Dinah Amante, BS¹, Emma L. Reuschel, PhD², Mansi Purwar, PhD², Aaron Christensen-Quick, PhD¹, Neiman Liu, MS¹, Viviane M. Andrade, PhD¹, Malissa C. Diehl, PhD¹, Snehal Wani, MS¹, Martyna Lupicka, PhD¹, Albert Sylvester, BS¹, Matthew P. Morrow, PhD¹, Patrick Pezzoli, BS¹, Trevor McMullan, MS¹, Abhijeet J. Kulkarni, MS², Faraz I. Zaidi, MS², Drew Frase, MS², Kevin Liaw, PhD², Trevor R.F. Smith, PhD¹, Stephanie J. Ramos, PhD¹, John Ervin, MD⁴, Mark Adams MD⁵, Jessica Lee, MPH¹, Michael Dallas, PhD¹, Ami Shah Brown, PhD, MPH¹, Jacqueline E. Shea, PhD¹, J. Joseph Kim, PhD¹, David B. Weiner, PhD², Kate E. Broderick, PhD¹, Laurent M. Humeau, PhD^{1#}, Jean D. Boyer, PhD¹, Mammen P. Mammen Jr., MD¹

*Authors contributing equally

Affiliations:

¹Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA

²Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, PA, 19104, USA

³Hospital of the University of Pennsylvania, Philadelphia, PA, USA

⁴Alliance for Multispecialty Research, Kansas City, MO, USA

⁵Alliance for Multispecialty Research, Lexington, KY, USA

Summary:

Two-milligram dose of INO-4800, a DNA-based vaccine encoding the SARS-CoV-2 spike protein, appears safe and well-tolerated and elicits humoral and cell-mediated immunity persisting to 6 months after a second dose. A third dose 6-10.5 months later significantly boosts immune responses.

Running Title: SARS-CoV-2 DNA Vaccine Can be Boosted

Abstract Word Count: 200

Text Word Count: 3494

Meeting presentations:

In part at ID Week (September 2021), Virtual (Abstract #: 571)

#Corresponding author:

Laurent M. Humeau, PhD

Inovio Pharmaceuticals

660 W. Germantown Pike, Suite #110

Plymouth Meeting, PA, 19462, USA.

Phone: (858) 410-3140

laurent.humeau@inovio.com

Alternate corresponding author:

Kimberly A. Kraynyak, PhD

Inovio Pharmaceuticals

660 W. Germantown Pike, Suite #110

Plymouth Meeting, PA, 19462, USA

Phone: (267) 440-4216

kim.kraynyak@inovio.com

Abstract

Background: Additional SARS-CoV-2 vaccines that are safe and effective as primary vaccines and boosters remain urgently needed to combat the COVID-19 pandemic. We describe the safety and durability of the immune responses following two primary doses and a homologous booster dose of an investigational DNA vaccine (INO-4800) targeting the full-length spike antigen.

Methods: Three dosage strengths of INO-4800 (0.5 mg, 1.0 mg, and 2.0 mg) were evaluated in 120 age-stratified healthy adults. Intradermal injection of INO-4800 followed by electroporation at 0 and 4 weeks preceded an optional booster 6-10.5 months after the second dose.

Results: INO-4800 appeared well tolerated, with no treatment-related serious adverse events. Most adverse events were mild and did not increase in frequency with age and subsequent dosing. A durable antibody response was observed 6 months following the second dose; a homologous booster dose significantly increased immune responses. Cytokine producing T cells and activated CD8+ T cells with lytic potential were significantly increased in the 2.0 mg dose group.

Conclusion: INO-4800 was well tolerated in a 2-dose primary series and as a homologous booster in all adults, including the elderly. These results support further development of INO-4800 for use as a primary vaccine and as a booster.

Keywords: SARS-CoV-2; Clinical trial; DNA Vaccine; INO-4800; COVID-19; Safety; Immunogenicity; Booster

Trial Registration: [ClinicalTrials.gov NCT04336410](https://clinicaltrials.gov/ct2/show/study/NCT04336410)

1 **Introduction**

2 Despite aggressive vaccination campaigns, most of the world's population remains unvaccinated
3 and susceptible to COVID-19, the disease caused by SARS-CoV-2[1]. The urgent need remains
4 for additional safe and effective vaccines that are affordable, scalable, and can be distributed to
5 countries where the infrastructure may not be supportive of ultra-cold chain transport and storage.

6 Attachment of SARS-CoV-2 to host cells is mediated by binding of the viral spike (S) protein to
7 angiotensin converting enzyme 2 (ACE2) receptors on host cells[2]. Humoral responses against
8 the spike protein prevent the virus from accessing host cells[3], and this strategy has led to the
9 development of several vaccines targeting SARS-CoV-2 (reviewed by[4, 5]).

10 INO-4800 is an investigational optimized DNA vaccine, encoding the SARS-CoV-2 S protein[6],
11 injected intradermally followed by in vivo electroporation[7]. This approach potentially offers
12 several advantages, including induction of humoral and cellular immunity, favorable tolerability
13 and thermal stability profiles, and ease of manufacture[8, 9]. Plasmid DNA-based products in
14 development by this sponsor have been shown to be stable at 2-8°C for 3-5 years, at room
15 temperature (25°C) for least 1 year, and at 37°C for 1 month (unpublished data), and is in line
16 with earlier reports on the stability of pharmaceutical grade plasmid DNA[10].

17 Preclinical studies have shown INO-4800 to be immunogenic[6], with durable cellular and
18 neutralizing antibody responses[11]. INO-4800 provided protection against viral challenge in non-
19 human primates with no evidence of vaccine-enhanced disease[12], and elicited neutralizing
20 antibodies reactive against multiple variants of concern (VOCs)[13].

21 The preliminary safety and immunogenicity of INO-4800 in both Phase 1 and Phase 2 clinical
22 studies have been previously reported[14, 15]. The earlier analysis[14] demonstrated that two
23 doses of INO-4800 administered one month apart were well tolerated in 38 healthy participants
24 18-50 years of age and induced neutralizing antibodies and/or T-cells. Here we describe the

25 durability of that response at 6 months following the second dose, as well as the safety and
26 immunogenicity of the 2-dose regimen in older and elderly participants, including following a
27 subsequent homologous booster dose.

28

29 **Methods**

30 Trial Design and Participants

31 This Phase 1, open-label, multi-center trial (NCT04336410) evaluated the safety, tolerability, and
32 immunogenicity of INO-4800 injected intradermally (ID) followed by electroporation (EP). A total
33 of 120 healthy participants without a known history of COVID-19 were assigned to receive a
34 0.5mg, 1.0mg, or 2.0mg dose of INO-4800 in a 2-dose regimen (weeks 0 and 4) and a subsequent
35 optional booster dose no earlier than 8 weeks after dose 2. An equal number of participants were
36 enrolled in each dose group (n=40) and further stratified by age groups [18-50 years of age; n=20,
37 51-64 years of age; n=10, and ≥65 years of age; n=10].

38 The trial was approved by the institutional review board of each clinical site, all participants
39 provided written informed consent prior to enrollment. The trial was conducted under current Good
40 Clinical Practices (GCP).

41

42 DNA Vaccine INO-4800

43 INO-4800 was previously described[6, 14] and encodes the full-length sequence of the SARS-
44 CoV-2 spike glycoprotein derived from the Wuhan strain based on an optimized synthetic

45 sequence created using a proprietary algorithm. The final vaccine drug product, manufactured
46 under Good Manufacturing Practices, was formulated at 10mg/mL in saline sodium citrate buffer.
47 INO-4800 is injected ID followed by EP using the CELLECTRA® 2000 device that generates a
48 controlled electric field at the injection site to enhance the cellular uptake and expression of the
49 DNA plasmid as previously described[16, 17]. The device delivers a total of four electrical pulses
50 per EP, each of 52 msec in duration, at current of 0.2 Amp and voltage of 40-200 per pulse.

51

52 Endpoints

53 Primary safety endpoints included incidence of adverse events (AEs) using the “Toxicity Grading
54 Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trial”
55 including frequency and severity of injection site reactions. Primary immunological endpoints
56 included the measurement of SARS-CoV-2 Spike glycoprotein antigen-specific binding antibodies
57 as well as the measurement of antigen-specific cellular immune responses by IFN- γ , ELISPOT
58 and flow cytometry assays. Endpoints reflected in this publication are inclusive of 6 months after
59 second dose (non-boosted participants) and, when applicable, 2 weeks after booster dose.

60

61 Trial Procedures

62 Vaccine was administered in 0.1 ml ID injections in the deltoid followed by EP at the injection site.
63 At each dosing visit, either a single injection for 0.5mg and 1.0mg dose groups or two injections
64 for 2.0mg dose group were given, one in each deltoid.

65 Forty participants 18-50 years were enrolled sequentially into 1.0mg and 2.0mg dose groups with
66 a safety run-in period[14]. The trial design was expanded to include older participants in all dosing
67 groups (including a 0.5mg dose level). Upon favorable safety assessment review by an

68 independent Data Safety Monitoring Board (DSMB) of Week 1 data for 0.5mg dose group
69 participants aged 51-64 years and ≥ 65 years, enrollment of the corresponding age strata in the
70 1.0mg and subsequently 2.0mg dose groups was initiated.

71 Participants were assessed for safety (complete blood count, serum chemistry, and urinalysis),
72 including local and systemic AEs, at screening, Week 0 (Dose 1), next day phone call, and Weeks
73 1, 4 (Dose 2), 6, 8, 12, 28, 40 and 52. Blood immunology collections occurred at all clinic visits
74 except Week 1. After the Week 12 visit, participants who consented to the optional booster dose
75 were transitioned to an extended schedule of events to include the booster dose (Dose 3) and
76 subsequent visits for safety at 2, 12, 24, 36, and 48 weeks following the booster dose with blood
77 immunology collections at all clinic visits except 36 weeks.

78 The DSMB reviewed laboratory and AE data for the participants up to 24 weeks after the second
79 dose (non-boosted) and 2 weeks after booster dose.

80

81 Protocol Eligibility

82 Key inclusion criteria included: healthy adults aged at least 18 years; and Body Mass Index of 18-
83 30kg/m² at screening. Key exclusion criteria included: individuals in a current occupation with high
84 risk of exposure to SARS-CoV-2; previous known exposure to SARS-CoV-2 or receipt of an
85 investigational product for the prevention or treatment of COVID-19; autoimmune or
86 immunosuppression as a result of underlying illness or treatment; hypersensitivity or severe
87 allergic reactions to vaccines or drugs; and medical conditions that increased risk for severe
88 COVID-19.

89

90 Immunogenicity Assessment Methods

91 Samples were collected at timepoints described above with screening and pre-dose 1 samples
92 considered baseline. Peripheral blood mononuclear cells (PBMCs) were collected as previously
93 described[14]. After isolation, PBMCs were stored in the vapor phase of a liquid nitrogen freezer
94 until analysis, while serum samples were stored at -80°C. Eight participants were excluded from
95 the immunogenicity analyses due to a positive ELISA titer to the SARS-CoV-2 nucleoprotein,
96 suggesting SARS-CoV-2 infection

97 SARS-CoV-2 Pseudovirus Neutralization Assay: Serum samples were measured using a
98 pseudovirus neutralization assay as described previously[15]. Data was reported as ID₅₀, which
99 is the reciprocal serum dilution resulting in 50% inhibition of infectivity by comparison to control
100 wells with no serum samples added. Supplementary methods show additional information.

101 SARS-CoV-2 Spike Enzyme-Linked Immunosorbent Assay (ELISA): Binding antibodies to SARS-
102 CoV-2 spike protein were measured by ELISA as described previously[15]. SARS-CoV-2 spike
103 antibody concentrations were determined by interpolation from a dilution curve of SARS-CoV-2
104 convalescent plasma with an assigned concentration of 20,000 Units/mL. Supplementary
105 methods show additional information.

106 SARS-CoV-2 Spike ELISpot Assay Description: The SARS-CoV-2 spike antigen-specific IFN- γ
107 T-cell response was measured as described previously[14]. Values were reported as the mean
108 spot-forming units per million PBMCs across three triplicate wells after background subtraction
109 using DMSO-only negative control wells. Supplementary methods show additional information.

110 INO-4800 SARS-CoV-2 Spike Flow Cytometry Assays: PBMCs were also assessed in
111 Intracellular Cytokine Staining (ICS) and Lytic Granule Loading (LGL) assays. The ICS assay was
112 performed as previously described[14]. The LGL assay was also performed as reported

113 previously[18] following stimulation with overlapping peptides to the full-length spike protein to
114 measure CD8+T cell activation and capacity to produce lytic proteins.

115 Statistical Analysis

116 No formal power analysis was applicable to this trial. Descriptive statistics were used to
117 summarize the safety endpoints based on the safety population: proportions of participants with
118 AEs, through 6 months following dose 2 (non-boosted participants) or 2 weeks following booster
119 dose. The safety population included all participants who received at least one dose of INO-4800
120 and were grouped by age and the dose of INO-4800. Post-hoc within subject analyses of post-
121 vaccination minus pre-vaccination paired differences in SARS-CoV-2 neutralization and ELISA
122 spike responses (on the natural log-scale, with a paired t-test), ELISpot responses (with Wilcoxon
123 signed-rank tests), and flow assay responses (with Wilcoxon signed-rank tests) were performed.

124 **Results**

125 Trial Population Demographics

126 Between 06 April 2020 and 07 July 2020, 154 participants were screened and 120 enrolled into
127 the trial (**Figure 1**). The median age was 50.5 years (range 18 to 86 years). Participants were
128 57.5% female (69/120) and 42.5% male (51/120) (**Table 1**). Most participants were white (94.2%,
129 113/120).

130

131 Vaccine Safety and Tolerability

132 A total of 117 of 120 (97.5%) participants received both doses. One participant in the 2.0 mg
133 group discontinued trial participation prior to receiving the second dose solely due to lack of
134 transportation to the clinical site. Two participants in the 0.5 mg group did not receive the second
135 dose due to exclusionary eligibility criteria (hypertension) having been determined following Dose
136 1; (**Figure 1**).

137 Ninety-nine of 120 (82.5%) participants consented to and received the booster dose,
138 approximately 6 to 10.5 months following the second dose. Reasons for not receiving booster
139 dose included receipt of another SARS-CoV-2 vaccine (available under Emergency Use
140 Authorization), new medical condition precluding participation (having had COVID-19, pregnancy
141 or hypertension), or loss to follow-up.

142 A total of 34 treatment-related local and systemic AEs were reported by 18 participants. Thirty-
143 one AEs were Grade 1 (mild) in severity and comprised mostly injection site reactions. Three
144 treatment-related Grade 2 (moderate) AEs were reported as lethargy, abdominal pain, and
145 injection site pruritus. There were no febrile reactions reported. No participants discontinued due
146 to AEs. No treatment-related SAEs were reported. There were no abnormal laboratory values that

147 were deemed treatment-related and clinically significant by the Investigators. There was no
148 increase in the number of participants who experienced related AEs in the 2.0 mg group (12.5%,
149 5/40), compared to that in the 1.0 mg group (15%, 6/40) or the 0.5 mg group (17.5%, 7/40). In
150 addition, there was no appreciable increase in the frequency of AEs with the second or booster
151 doses when compared to the first dose (**Figure 2**). A decrease in frequency of treatment-related
152 AEs in the older and elderly age cohorts was observed when compared to the younger age group
153 (**Supplementary Table 4**).

154

155 *INO-4800 induces durable humoral immune responses capable of being boosted*: Induction of
156 antibodies against SARS-CoV-2 following vaccination with INO-4800 was measured from sera.
157 The functionality of antibodies was assessed using a pseudovirus neutralization assay. All dose
158 groups induced neutralizing antibodies that peaked two weeks post second dose (GMTs- 14.9,
159 19.1, 54.1 in the 0.5 mg, 1.0 mg and 2.0 mg dose groups, respectively) (**Figure 3A, left panel**,
160 **Supplementary Table 1**). These increased responses were statistically significant over baseline
161 in the 2.0 mg dose group for each time point through study week 28, approximately 6 months
162 after dose 2 (**Figure 3A, table**). Following administration of a booster dose, statistically significant
163 increases over pre-boost titers were observed in all dose groups (GMTs- 58.7, 76.1, 100 in the
164 0.5 mg, 1.0 mg and 2.0 mg dose groups, respectively; all $P < 0.001$) (**Figure 3A, right panel**,
165 **Supplementary Table 1**). The 2.0 mg dose group had a 12.8 (95%CI 6.3, 26.0) geometric fold
166 rise (GMFR) over pre-boost titers, the highest of any dose group. Neutralization titers by
167 participant age are shown in **Supplementary Figure 1A**; GMTs were numerically lower in the
168 older age groups but statistically significantly higher than baseline at week 6 in the 2.0 mg dose

169 group. Plasma samples from convalescent samples had a GMT of 922 and ranged from 10 to
170 13,249 (**Supplementary Figure 2A**).

171 Antibodies to the spike trimer protein were measured in a binding ELISA. All three groups
172 exhibited binding antibodies that peaked four weeks following dose 2 (Geometric Mean Titers,
173 GMTs- 428.5, 595.9, 678.0 in the 0.5 mg, 1.0 mg and 2.0 mg dose groups, respectively) (**Figure**
174 **3B, left panel, Supplementary Table 2**). Increases over baseline were observed in all
175 participants who received the 2.0 mg dose, but not in all participants in the other groups, and
176 GMTs were statistically significantly higher than baseline 6 months following dose 2 (GMTs-
177 250.1, 215.3, 407.2 in the 0.5 mg, 1.0 mg and 2.0 mg dose groups, respectively; all $P \leq 0.026$).
178 Following administration of a booster dose, statistically significant increases over pre-boost titers
179 were observed in all dose groups (GMTs- 1963.8, 3685, 5953 in the 0.5 mg, 1.0 mg and 2.0 mg
180 dose groups, respectively; all $P \leq 0.007$) (**Figure 3B, right panel, Supplementary Table 2**). The
181 2.0 mg dose group had a 20.8 (95%CI 13.9, 31.2) GMFR over pre-boost titers which was the
182 highest of any dose group. ELISA binding titers by participant age are shown in **Supplementary**
183 **Figure 1B**. Plasma samples from convalescent samples had a GMT of 19,444 and ranged from
184 330 to 247,200 (**Supplementary Figure 2B**).

185 *INO-4800 induces cellular immune responses capable of being boosted*

186 Interferon-gamma ($IFN\gamma$) ELISpot was performed on PBMCs. Increases in spot forming units
187 (SFU) per million PBMCs over baseline are shown in **Figure 4A, left panel**. Magnitudes of $IFN\gamma$
188 peaked at week 6 for the 0.5 mg and 2.0 mg dose groups (median 19.4 and 43.3, respectively)
189 and at week 8 for the 1.0 mg dose group (median 17.8). Six months following dose 2, magnitudes
190 remained high in the 2.0 mg dose group (median 19.6). Of note, magnitudes in the 1.0 mg and
191 2.0 mg dose groups were statistically significantly increased following the booster dose ($P=0.018$
192 and $P=0.008$, respectively) (**Figure 4A, right panel**). The 2.0 mg dose group had a difference in

193 medians of 10 following the booster, resulting in the highest post-boost increase of any dose
194 group. ELISpot responses by participant age are shown in **Supplementary Figure 3A**.

195 *INO-4800 induces cytokine producing T cells and activated CD8+T cells with lytic potential*

196 The contribution of SARS-CoV-2 specific CD4⁺ and CD8⁺ T cells was assessed by intracellular
197 cytokine staining (ICS) on participants following 2 doses, **Figure 4B-C**. The median frequency of
198 CD4⁺T cells producing IFN γ increased following vaccination in all three dose groups of INO-4800,
199 and the frequency of CD4⁺T cells producing TNF α was statistically significantly increased in the
200 2.0 mg dose group (P<0.001) (**Figure 4B**). The frequency of CD8⁺T cells producing TNF α was
201 statistically significantly increased following vaccination in all three dose groups of INO-4800 (All
202 P \leq 0.041) (**Figure 4C**). The 2.0 mg dose group had the highest difference in medians for CD8⁺T
203 cells producing any response, IFN γ and TNF α (0.066, 0.026, and 0.011 respectively). Responses
204 by participant age are shown in **Supplementary Figure 3B-C**.

205 SARS-CoV-2 specific CD8⁺T cells were also characterized on a subset of participants with
206 remaining sample following 3 doses by a flow cytometry assay that included activation markers
207 CD69 and CD137. The median frequency of CD8⁺CD69⁺CD137⁺ cells increased following
208 immunization with 2.0 mg of INO-4800, with a difference in the medians of 0.072 (**Figure 5A, left**
209 **panel**). Further characterization of these activated cells, including the co-expression of proteins
210 utilized in cytolytic killing (granzyme A, granzyme B, perforin or granulysin) revealed a statistically
211 significant increase in both the 1.0 mg (P=0.008) and 2.0 mg (P=0.003) dose groups (**Figure 5A**
212 **middle and right panels**). The 2.0 mg dose group had a difference in medians of 0.085 in the
213 CD69⁺CD137⁺ population co-expressing perforin and granzymes A and B and 0.054 in the
214 population co-expressing granulysin. CD8⁺T cells expressing the activation marker CD38 and
215 proliferation marker Ki67 were also assessed (**Figure 5B and C, respectively**). The frequency
216 of SARS-CoV-2 specific CD38⁺CD8⁺T cells statistically significantly increased following 2.0 mg

217 of INO-4800 ($P=0.016$), with a difference in medians of 1.45 (**Figure 5B, left panel**).

218 CD38+CD8+T cells with lytic potential (**Figure 5B middle and right panels**) statistically

219 significantly increased following 2.0 mg of INO-4800 ($P<0.001$). Following immunization with 2.0

220 mg of INO-4800, the mean frequency of activated CD8+T cells expressing granzymes A and B

221 and perforin was 1.7% with a difference in medians of 0.710 and those expressing granulysin was

222 1.8% with a difference in medians of 0.433 (**Figure 5B middle and right panels**). Statistically

223 significant increases in the frequency of these CTL phenotypes were also observed in the 1.0 mg

224 dose group ($P\leq 0.012$) (**Figure 5B middle and right panels**). The 2.0 mg dose group had the

225 highest frequencies of CD8+T cells expressing Ki67 with a difference in medians of 0.367 and

226 Ki67 with cytolytic proteins: 0.296 (GrzA+GrzB+Prf+) and 0.230 (Gnly+). All three Ki67+

227 populations were statistically significantly increased in the 2.0 mg dose group ($P\leq 0.001$; **Figure**

228 **5C**). The 2.0 mg dose group consistently showed the highest median responses across all

229 phenotypes assessed compared to the other groups.

230

231 **Discussion**

232 This report provides results for the expansion of a Phase 1 trial to include older and elderly

233 participants and an optional booster dose with the aim to evaluate the safety, tolerability, and

234 immunogenicity of INO-4800, a SARS-CoV-2 vaccine encoding the S protein[14], including the

235 immune responses 6 months following dose 2 and 2 weeks following the optional booster dose.

236 INO-4800 appeared to be well-tolerated at all three dose levels, with no treatment-related serious

237 adverse events (SAEs) reported. Most AEs were mild in severity and did not increase in frequency

238 with age and subsequent dosing. These results are consistent with the severity of AEs and lack

239 of treatment-related SAEs observed in the U.S. Phase 2 trial comparing the 1.0 mg and 2.0 mg

240 doses of INO-4800 in approximately 400 subjects[15] and those studies conducted outside the

241 U.S. by Inovio collaborators (International Vaccine Institute, Advaccine – manuscripts in
242 preparation). The lower frequency of treatment-related AEs reported by older and elderly
243 participants in our study is consistent with findings of other studies evaluating SARS-CoV-2
244 vaccines[19, 20]. Weaker inflammatory reactions consequent to immunosenescence may explain
245 the lower incidence of AEs among elderly participants[21, 22].

246 Induction of both humoral and cellular responses were observed across all three dose groups,
247 inclusive of binding and neutralizing antibodies and cytokine producing T cells as well as
248 exhibiting lytic potential. Immunization with the 2.0 mg dose resulted in the highest GMTs of
249 neutralizing and binding antibodies as well as the highest magnitudes of IFN γ production to SARS-
250 CoV-2 of any dose in all age groups tested, and the increases in antibody levels were statistically
251 significant above baseline at 6 months following dose 2. Importantly, increases in both humoral
252 and cellular immune responses were statistically significant following the booster dose.

253 The contribution of the CD8+T cell response to vaccine efficacy has become increasingly
254 recognized as they have been detected early after vaccination[23] and due to their role in
255 controlling infection[24, 25]. Specifically, it has been established that CD8+T cells expressing
256 cytokines such as IFN γ and TNF α as well as markers involved in activation status and proliferation
257 such as CD38 and Ki67 contribute to limiting disease severity during SARS-CoV-2 infection[24].
258 Additional studies have identified the expression of CD69 and CD137 on SARS-CoV-2 specific
259 CD8+T cells being associated with less severe disease[25]. This expanded Phase 1 trial
260 demonstrates that immunization with INO-4800 induces SARS-CoV-2 specific CD8+T cells
261 exhibiting these specific characteristics, suggesting the induction of a vaccine-induced cellular
262 response that has potential to protect against severe COVID-19. As VoCs continue to emerge,
263 the generation of cross-reactive activated CD8+T cells with lytic potential is likely to play an
264 important role in preventing severe disease. We have previously demonstrated that vaccination
265 with INO-4800 induces T cells and neutralizing antibodies that are active against the parental

266 SARS-CoV-2 strain as well as the B.1.1.7, B.1.351, and P.1 VoCs[26]. We acknowledge
267 limitations to this trial that include the relatively small study population and the limited number of
268 PBMCs available for testing across more than one assay. This trial was not powered to formally
269 compare immune responses between dose groups or age stratifications. In addition, due to
270 different immune assays and methodologies employed by various groups, it is not possible to
271 directly compare immune responses observed in this trial to those elicited from other vaccine
272 platforms or to determine if the magnitudes observed in this trial are sufficient to confer clinical
273 benefit.

274 The immune responses observed in the current trial and in our larger Phase 2 trial[15] support
275 advancing the 2.0 mg dose of INO-4800 to a Phase 3 efficacy evaluation. This dose has elicited
276 the highest binding and neutralizing antibody titers, the highest T-cell cytokine production from
277 both CD4+ and CD8+T cells, and the highest expression of markers associated with attenuation
278 of severe COVID-19 on CD8+T cells.

279 This trial demonstrated that immune responses elicited by a 2-dose primary series of INO-4800
280 could be boosted by a third dose without safety or tolerability concerns and positions INO-4800
281 as an important candidate for continued development as a stand-alone SARS-CoV-2 vaccine, as
282 well as for continued examination in combination approaches. The potential ability to administer
283 INO-4800 multiple times, with high tolerability, along with its ease of scalability and
284 thermostability, contribute to its potential value in combatting the COVID-19 pandemic.

Declaration of Interests

KAK, EB, JA, MG, DA, ACQ, NL, VA, MD, SW, ML, AS, MPM, PP, TM, TRFS, SJR, JL, MD, ASB, JES, JJK, KEB, LMH, JDB, MPM, Jr. report grants from Coalition for Epidemic Preparedness Innovations, during the conduct of the trial; other from Inovio Pharmaceuticals, outside the submitted work. PT, ELR, MP, AJK, FIZ, DF, KL, JE, MA, and DBW report grants from Coalition for Epidemic Preparedness Innovations, during the conduct of the trial. D.B.W. participates in industry collaborations and has received remuneration for individual services. In the interest of disclosure, D.B.W. reports the following paid associations with commercial partners: Pfizer (Advisory Board), Geneos (Advisory, SRA), Advaccine (Advisory) Astrazeneca (Advisory, Speaker), Inovio (BOD, SRA, Stock ownership), Sanofi (Advisory Board), BBI (Advisory Board, SRA). All other authors declare no potential conflicts of interest.

Funding

This work is funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and Inovio Pharmaceuticals, Inc.

Acknowledgments

The investigators and sponsor express their gratitude for the contribution of all the trial participants and the invaluable advice of the independent Data Safety Monitoring Board. Feedback from the peer reviewers is gratefully acknowledged. We also acknowledge the broader support from the various teams within Inovio Pharmaceuticals (Ning Jiang, MD, PhD; Greta Kcomt Del Rio, BS; Alysia Ryan, BS; Dennis Van De Goor, MS; Kelly Morales, BS; Jacob Walton, BS; Srujan Vadlamudi, BS; David Valenta, PhD; EJ Brandreth, MBA; Dan Jordan, BS; Robert J. Juba Jr, MS; Stephen Kemmerrer, BSME, MBA, PE; Timothy Herring, MPH; Susan Duff, BS; and Prasad

Kulkarni, PhD, CMPP), the Wistar Institute (Dr. Ziyang Xu and Edgar Tello Ruiz), the National Infections Service, Public Health England (Naomi Coombes, PhD and Mike Elmore, PhD), Hospital of the University of Pennsylvania (Joseph Quinn, RN), and the Alliance for Multispecialty Research, Kansas City, MO and Lexington, KY.


References

1. Katz IT, Weintraub R, Bekker LG, Brandt AM. From Vaccine Nationalism to Vaccine Equity - Finding a Path Forward. *N Engl J Med* **2021**; 384:1281-3.
2. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* **2020**; 181:281-92.e6.
3. Carrillo J, Izquierdo-Useros N, Avila-Nieto C, Pradenas E, Clotet B, Blanco J. Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. *Biochem Biophys Res Commun* **2021**; 538:187-91.
4. Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. *Infect Dis Poverty* **2021**; 10:132.
5. Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. *Front Immunol* **2021**; 12:714170.
6. Smith TRF, Patel A, Ramos S, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. *Nat Commun* **2020**; 11:2601.
7. Gary EN, Weiner DB. DNA vaccines: prime time is now. *Curr Opin Immunol* **2020**; 65:21-7.
8. Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the Cold Reality of mRNA Vaccine Stability. *J Pharm Sci* **2021**; 110:997-1001.
9. Liu MA. A Comparison of Plasmid DNA and mRNA as Vaccine Technologies. *Vaccines (Basel)* **2019**; 7:37.
10. Middaugh CR, Evans RK, Montgomery DL, Casimiro DR. Analysis of plasmid DNA from a pharmaceutical perspective. *J Pharm Sci* **1998**; 87:130-46.
11. Patel A, Walters J, Reuschel EL, et al. Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model. *bioRxiv* **2020**.
12. Gooch KE, Smith TRF, Salguero FJ, et al. One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model. *Vaccine* **2021**; 39:4885-94.
13. Walters JN, Schouest B, Patel A, et al. Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. *bioRxiv* **2021**:2021.10.27.466163.
14. Tebas P, Yang S, Boyer JD, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. *EClinicalMedicine* **2021**; 31:100689.
15. Mammen MP, Tebas P, Agnes J, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure. *medRxiv : the preprint server for health sciences* **2021**:2021.05.07.21256652.
16. Tebas P, Roberts CC, Muthumani K, et al. Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report. *N Engl J Med* **2017**.
17. Tebas P, Kraynyak KA, Patel A, et al. Intradermal SynCon(R) Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers. *J Infect Dis* **2019**; 220:400-10.
18. Aggarwal C, Cohen RB, Morrow MP, et al. Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis. *Vaccines (Basel)* **2020**; 8.
19. Chen M, Yuan Y, Zhou Y, et al. Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. *Infect Dis Poverty* **2021**; 10:94.

20. Wu Q, Dudley MZ, Chen X, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. *BMC Med* **2021**; 19:173.
21. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. *Nature reviews Immunology* **2009**; 9:185-94.
22. Prelog M. Differential approaches for vaccination from childhood to old age. *Gerontology* **2013**; 59:230-9.
23. Kalimuddin S, Tham CYL, Qui M, et al. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. *Med (N Y)* **2021**; 2:682-8 e4.
24. Chen Z, John Wherry E. T cell responses in patients with COVID-19. *Nature reviews Immunology* **2020**; 20:529-36.
25. Rydzynski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell* **2020**; 183:996-1012 e19.
26. Andrade VM, Christensen-Quick A, Agnes J, et al. INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants. *NPJ Vaccines* **2021**; 6:121.

Table 1- Participant Demographics

Variable	Statistic	0.5 mg (N=40)	1mg (N=40)	2mg (N=40)	Total (N=120)
Sex					
Male	n (%)	18 (45.0)	17 (42.5)	16 (40.0)	51 (42.5)
Female	n (%)	22 (55.0)	23 (57.5)	24 (60.0)	69 (57.5)
Race					
White	n (%)	40 (100)	38 (95.0)	35 (87.5)	113 (94.2)
Black or African American	n (%)	0	1 (2.5)	1 (2.5)	2 (1.7)
Asian	n (%)	0	1 (2.5)	4 (10.0)	5 (4.2)
Ethnicity					
Hispanic or Latino	n (%)	3 (7.5)	0	0	3 (2.5)
Not Hispanic or Latino	n (%)	35 (87.5)	40 (100)	40 (100)	115 (95.8)
Not Reported	n (%)	2 (5.0)	0	0	2 (1.7)
Age (years)	N	40	40	40	120
	Mean (SD)	50.7 (15.30)	49.2 (16.75)	50.7 (17.90)	50.2 (16.56)
	Median	52.5	51.0	50.5	50.5
	Min, Max	23, 76	18, 73	19, 86	18, 86






Figure 2- Related systemic and local adverse events. Post First Dose, N=120 (N=40 in each dose group), Post Second Dose, N=117 (N=38 in the 0.5 mg dose group, N=40 in the 1.0 mg dose group and N=39 in the 2.0 mg dose group, and Post Third Dose, N=99 (N=33 in the 0.5 mg dose group, N=31 in the 1.0mg dose group and N=35 in the 2.0 mg dose group)




Figure 3- INO-4800 induces antibodies to SARS-CoV-2. A) Functional antibodies were assessed using a pseudovirus neutralization assay. The inhibition dilution where 50% neutralization occurs (ID₅₀) is plotted. The dotted line represents the lowest dilution tested in the assay (1:20). The left panel includes n=40 participants in the 0.5 mg dose group, n=35 participants in the 1.0 mg dose group and n=36 participants in the 2.0 mg dose group. The right panel includes n=33, n=26 and n=31 participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B) Binding antibody concentrations to the Spike trimer were measured using ELISA. The left panel includes n=40 participants in the 0.5 mg dose group, n=35 participants in the 1.0 mg dose group and n=36 participants in the 2.0 mg dose group. The right panel includes n=31, n=29 and n=32 participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. Open symbols represent individual participants, the box extends from the 25th to the 75th percentile, line inside the box is

the median, and the whiskers extend from the minimum to maximum values. The mean is denoted with a “+” sign. Paired t test was used to assess significance versus baseline. The dose groups are represented by orange triangles (0.5 mg), blue circles (1.0 mg) and green squares (2.0 mg).




Figure 4- INO-4800 induces cellular responses to SARS-CoV-2 Spike. A) Longitudinal increases in spike antigen specific spot forming units per 10⁶ PBMCs over baseline in the IFN-g ELISpot are plotted. The left panel includes n=40 participants in the 0.5 mg dose group, n=35 participants in the 1.0 mg dose group and n=36 participants in the 2.0 mg dose group. The right panel includes n=31, n=30 and n=34 participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B-C) Intracellular cytokine staining for IFN-g (purple) IL-2 (gray), TNF-a (blue) or any of the three cytokines (red) are plotted from samples collected at baseline or post-dose 2. The graphs include n=40 participants in the 0.5 mg dose group and n=39 participants in the 1.0 mg and 2.0 mg dose groups. Open symbols represent individual participants, the box extends from the 25th to the 75th percentile, line inside the box is the median, and the whiskers extend from

the minimum to maximum values. The mean is denoted with a “+” sign. Wilcoxon signed-rank was used to assess significance versus baseline. The dose groups are represented by triangles (0.5 mg), circles (1.0 mg) and squares (2.0 mg).




Figure 5- INO-4800 induces spike specific activated CD8+T cells with lytic potential. A lytic granule loading flow cytometry assay was used to further characterize CD8+T cells and an example gating strategy is shown in (A). The expression of the activation markers CD69 and CD137 (B), CD38 (C), and the proliferation marker Ki67 (D) from samples collected at baseline or post-dose 2. The expression of proteins found in lytic granules: granzymes A (GrzA) and B (GrzB), perforin (Prf) and granulysin (Glny) were assessed together with activation/proliferation subset. The graphs include n=4 participants in the 0.5 mg dose group and n=10 participants in the 1.0 mg dose group and n=13 in the 2.0 mg dose group. Open symbols represent individual participants, the box extends from the 25th to the 75th percentile, line inside the box is the median, and the whiskers extend from the minimum to maximum values. The mean is denoted with a “+”

sign. Wilcoxon signed-rank was used to assess significance versus baseline. The dose groups are represented by orange triangles (0.5 mg), blue circles (1.0 mg) and green squares (2.0 mg).

Supplementary Methods

Study Design and Enrollment Progression

Participants enrolled at one of three locations in the U.S.: The University of Pennsylvania Clinical Trials Unit in Philadelphia, PA; the Alliance for Multispecialty Research in Kansas City, MO; and the Alliance for Multispecialty Research in Lexington, KY.

Assessment of SARS-CoV-2 Specific Immune Responses

SARS-CoV-2 Spike Enzyme-Linked Immunosorbent Assay (ELISA) description: Costar high bind plates were coated by incubating 1-3 days at 2-8°C with 2.0 µg/mL of recombinant SARS-CoV-2 spike protein trimer (Acro Biosystems; SPN-C52H9) which contains amino acids 16-1213 of the original Wuhan-Hu-1 isolate spike protein (ascension# QHD43416.1). The protein contains six proline substitutions for trimer stabilization and two alanine substitutions to eliminate the furin cleavage site. Coated plates were blocked with Starting Block (Thermo Scientific), followed by the addition of study samples, diluted 1/20 in Starting Block buffer. Plates were incubated for 1 hour, and then washed three times in PBS-tween. 1/1000-diluted anti-human IgG HRP conjugate (BD Pharmingen; 555788) was added, and plates were incubated for an additional hour. Plates were washed three times in PBS-tween, and SureBlue TMB substrate (SeraCare) was added. Assay plates were developed for approximately 9 minutes, and the color development was stopped by the addition of TMB Stop Solution (SeraCare). SARS-CoV-2 spike antibody concentrations were assigned to study samples by interpolation from a 4-parameter logistic model fit to a dilution curve of SARS-CoV-2 convalescent plasma. The convalescent plasma reference material (Aalto Bio Reagents Ltd) collected from a single convalescent donor >28 days after symptom onset from a PCR-confirmed SARS-CoV-2 test was arbitrarily assigned a concentration of 20,000 Units per mL. This sample was used as a control to standardize IgG responses across participant samples.

SARS-CoV-2 Pseudovirus Neutralization Assay

Briefly, heat inactivated study serum samples were serially diluted and incubated for 90 minutes with a SARS-CoV-2-DeltaCT pseudovirus which is based on an HIV/luciferase reporter vector and expresses both SARS-CoV-2 spike protein and luciferase. After incubation, the pseudovirus/serum mixture was added to CHO target cells with stable ACE2 expression. After incubating the pseudovirus, serum, and cells together at 37°C for 72h, a britelite™ Plus luminescence reporter gene assay system (Perkin Elmer) was used to lyse cells and luminescence was measured using a Biotek plate reader.

SARS-CoV-2 Spike ELISpot Assay Description

Briefly, 300,000 peripheral mononuclear cells (PBMCs) per well were stimulated overnight in triplicate wells of a pre-coated IFN- γ ELISpot plate (MabTech) using 200 ng per peptide per well (1 μ g/mL per peptide final concentration) of a single peptide pool consisting of 15-mer peptides that overlapped by 9 residues and spanned the full-length spike protein. The next day, plates were developed as according to the manufacturer's instructions (MabTech, Human IFN-g ELISpot Plus). A CTL S6 Micro Analyzer (CTL) with *ImmunoCapture* and *ImmunoSpot* software was used to scan and count spots corresponding to IFN- γ secreting cells. The ELISpot assay was performed in several batches due to the longevity of the study- the week 0 timepoint is run with each post-dose batch in order to have an appropriate baseline control. To most accurately represent the data, the baseline sample is subtracted from the post dose sample run in the same batch. The average of all week 0 values is 8.2 SFU/10⁶ and the median is 3.3 SFU/10⁶.

Supplementary Data

Supplementary Table 1: Geometric Mean Titers (GMT) in the pseudovirus neutralization assay

Dose Group	Week 0		Week 6			Week 8			Week 12			Week 28		
	N	GMT (95% CI)	N	GMT (95% CI)	P value	N	GMT (95% CI)	P value	N	GMT (95% CI)	P value	N	GMT (95% CI)	P value
0.5 mg	40	3.01 (1.97, 4.60)	40	14.94 (7.90, 28.25)	<0.001	40	6.00 (3.23, 11.17)	<0.001	39	3.65 (1.00, 101.0)	0.018	35	8.17 (1.00, 106.0)	<0.001
1.0 mg	35	6.18 (1.00, 235.0)	35	19.07 (8.79, 41.37)	0.003	35	14.79 (6.93, 31.55)	0.005	35	12.50 (5.75, 27.19)	0.023	21	7.00 (2.57, 19.03)	0.308
2.0 mg	36	3.50 (2.12, 5.78)	36	54.15 (31.46, 93.21)	<0.001	36	16.13 (7.39, 35.23)	<0.001	36	11.37 (5.93, 21.80)	0.009	19	11.87 (4.58, 30.76)	0.036

P values compare titers at each study week with those at Week 0

Dose Group	Pre-boost		Post-boost	
	N	GMT (95% CI)	N	GMT (95% CI)
0.5 mg	28	9.6 (4.6, 20.02)	31	58.73 (32.92, 104.75)
1.0 mg	22	7.61 (2.92, 19.84)	25	76.12 (35.18, 164.69)
2.0 mg	28	7.65 (3.75, 15.62)	30	100.0 (51.46, 194.33)

Supplementary Table 2: Geometric Mean Titers (GMT) in ELISA

Dose Group	Week 0		Week 4			Week 6			Week 8			Week 12			Week 28		
	N	GMT (95% CI)	N	GMT (95% CI)	P value	N	GMT (95% CI)	P value	N	GMT (95% CI)	P value	N	GMT (95% CI)	P value	N	GMT (95% CI)	P value
0.5 mg	40	103.55 (78.0, 137.46)	40	173.47 (110.93, 271.25)	0.035	40	333.54 (201.16, 553.02)	0.002	40	428.45 (279.42, 656.97)	<0.001	40	330.47 (214.29, 509.66)	0.001	40	250.08 (160.91, 388.67)	0.019
1.0 mg	35	83.5 (55.04, 126.7)	35	133.89 (76.13, 235.47)	0.007	35	337.78 (187.26, 609.28)	<0.001	35	595.95 (343.01, 1035.40)	<0.001	35	371.23 (220.08, 626.19)	<0.001	25	215.26 (113.62, 407.82)	0.026
2.0 mg	36	100.69 (70.9, 143.01)	36	236.7 (144.59, 387.48)	0.004	36	653.59 (380.01, 1124.13)	<0.001	36	677.97 (414.95, 1107.72)	<0.001	36	468.35 (305.26, 718.57)	<0.001	19	407.15 (239.95, 690.85)	0.012

P values compare titers at each study week with those at Week 0

Dose Group	Pre-boost		Post-boost	
	N	GMT (95% CI)	N	GMT (95% CI)
0.5 mg	31	292.65 (199.21, 429.93)	31	1963.77 (1111.61, 3469.2)
1.0 mg	29	261.71 (156.33, 438.14)	29	3685.49 (1992.72, 6816.2)
2.0 mg	32	285.91 (198.45, 411.91)	32	5953.14 (3616.44, 9799.6)

Supplementary Table 3: Spike-specific SFU/10⁶ PBMCs in the IFN- γ ELISpot assay

Dose Group	Week 6		Week 8		Week 12		Week 28	
	N	Median SFU/10 ⁶ PBMCs (95% CI)	N	Median SFU/10 ⁶ PBMCs (95% CI)	N	Median SFU/10 ⁶ PBMCs (95% CI)	N	Median SFU/10 ⁶ PBMCs (95% CI)
0.5 mg	40	19.4 (11.1, 23.3)	38	10.0 (4.4, 25.6)	36	10.6 (6.7, 26.7)	38	1.1 (1.0, 3.3)
1.0 mg	34	7.2 (2.8, 20.0)	33	17.8 (4.4, 27.8)	32	13.3 (6.7, 28.9)	22	6.5 (1.0, 20.6)
2.0 mg	33	43.3 (24.4, 70.0)	35	24.4 (18.9, 57.8)	32	27.8 (11.1, 54.4)	19	19.6 (5.9, 47.8)

Median of background subtracted magnitudes

95% CI = 95% Non-parametric confidence intervals for the median

Dose Group	Pre-boost		Post-boost	
	N	Median SFU/10 ⁶ PBMCs (95% CI)	N	Median SFU/10 ⁶ PBMCs (95% CI)
0.5 mg	31	6.7 (4.4, 12.2)	31	10.0 (6.7, 18.9)
1.0 mg	29	6.7 (3.3, 12.2)	28	8.3 (3.3, 17.8)
2.0 mg	33	6.7 (3.3, 22.2)	31	16.7 (8.9, 47.8)

95% CI = 95% Non-parametric confidence intervals for the median

Supplementary Table 4: Summary of treatment-related Adverse Events by Age, Term, and

Dose: Treatment related AEs were reported by A) twelve 18-50 year old participants (20%) reported B) five 51-64 year old participants (16.7%) and C) one \geq 65 year old participant (3.3%). All AEs were Grade 1 (mild) in severity with the exception of Grade 2 (moderate) lethargy, abdominal pain, and injection site pruritus. In case of multiple events, a participant is counted only once per system organ class and once per preferred term.

A)

System Organ Class Preferred Term	18-50 Years, n (%)			
	INO-4800 0.5 mg (N=20)	INO-4800 1.0 mg (N=20)	INO-4800 2.0 mg (N=20)	Total (N=60)
At least one related TEAE	6 (30.0)	4 (20.0)	2 (10.0)	12 (20.0)
General disorders and administration site conditions	6 (30.0)	4 (20.0)	1 (5.0)	11 (18.3)
Injection site erythema	1 (5.0)	3 (15.0)	0	4 (6.7)
Injection site pain	2 (10.0)	2 (10.0)	1 (5.0)	5 (8.3)
Injection site pruritus	3 (15.0)	0	0	3 (5.0)
Fatigue	1 (5.0)	0	0	1 (1.7)
Feeling hot	1 (5.0)	0	0	1 (1.7)
Injection site swelling	0	1 (5.0)	0	1 (1.7)
Gastrointestinal disorders	0	1 (5.0)	1 (5.0)	2 (3.3)
Abdominal pain upper	0	1 (5.0)	0	1 (1.7)
Nausea	0	0	1 (5.0)	1 (1.7)
Musculoskeletal disorders	0	1 (5.0)	0	1 (1.7)
Myalgia	0	1 (5.0)	0	1 (1.7)
Nervous system disorders	0	1 (5.0)	0	1 (1.7)
Headache	0	1 (5.0)	0	1 (1.7)
Lethargy	0	1 (5.0)	0	1 (1.7)
Skin and subcutaneous tissue disorders	1 (5.0)	0	0	1 (1.7)
Pruritus	1 (5.0)	0	0	1 (1.7)
Rash	1 (5.0)	0	0	1 (1.7)

B)

System Organ Class Preferred Term	51-64 Years, n (%)			
	INO-4800 0.5 mg (N=10)	INO-4800 1.0 mg (N=10)	INO-4800 2.0 mg (N=10)	Total (N=30)
At least one related TEAE	0	2 (20.0)	3 (30.0)	5 (16.7)
General disorders and administration site conditions	0	2 (20.0)	3 (30.0)	5 (16.7)
Injection site pain	0	1 (10.0)	1 (10.0)	2 (6.7)
Injection site pruritus	0	0	1 (10.0)	1 (3.3)
Injection site induration	0	1 (10.0)	0	1 (3.3)
Injection site coldness	0	0	1 (10.0)	1 (3.3)
Fatigue	0	0	1 (10.0)	1 (3.3)
Respiratory, thoracic, and mediastinal disorders	0	0	1 (10.0)	1 (3.3)
Dyspnea	0	0	1 (10.0)	1 (3.3)


C)

System Organ Class Preferred Term	≥65 Years, n (%)			
	INO-4800 0.5 mg (N=10)	INO-4800 1.0 mg (N=10)	INO-4800 2.0 mg (N=10)	Total (N=30)
At least one related TEAE	1 (10.0)	0	0	1 (3.3)
General disorders and administration site conditions	1 (10.0)	0	0	1 (3.3)
Injection site pain	1 (10.0)	0	0	1 (3.3)


Supplementary Figure 1: INO-4800 induces antibodies to SARS-CoV-2 across all age groups 18-50, 51-64 and ≥ 65 year olds

A) Functional antibodies were assessed using a pseudovirus neutralization assay. The inhibition dilution where 50% neutralization occurs (ID_{50}) is plotted. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 ≥ 65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 ≥ 65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 ≥ 65 year olds). The right panel includes only participants with paired data available n=26 (n=12 18-50 year olds, n=9 51-64 year olds and n=5 ≥ 65 year olds), n=21 (n=11 18-50 year olds, n=6, 51-64 year olds and n=4 ≥ 65 year olds) and n=27 (n=15 18-50 year olds, n=5 51-64 year olds and n=7 ≥ 65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively.

B) Binding antibody concentrations to the Spike trimer were measured using ELISA. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 ≥ 65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 ≥ 65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 ≥ 65 year olds). The right panel includes only participants with paired data available n=31 (n=16 18-50 year olds, n=8 51-64 year olds and n=7 ≥ 65 year olds), n=29 (n=13 18-50 year olds, n=8, 51-64 year olds and n=8 ≥ 65 year olds) and n=32 (n=15 18-50 year olds, n=7 51-64 year olds and n=10 ≥ 65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. Open symbols represent individual participants, the horizontal line represents the GMT and the whiskers extend to the 95%CI values. Paired t test was used to assess significance versus baseline. The dose groups are represented by orange triangles (0.5 mg), blue circles (1.0 mg) and green squares (2.0 mg).




B



Supplementary Figure 2: Antibody responses in SARS-CoV-2 convalescent donors.

Plasma from convalescent donors (n=38) was obtained. A) Functional antibodies were assessed using a pseudovirus neutralization assay. The inhibition dilution where 50% neutralization occurs (ID_{50}) is plotted. B) Binding antibody concentrations to the Spike trimer were measured using ELISA.





Supplementary Figure 3: INO-4800 induces cellular responses to SARS-CoV-2 Spike across all age groups (18-50, 51-64, and ≥ 65 years).


A) Longitudinal increases in spike antigen specific spot forming units per 10^6 PBMCs over baseline in the IFN-g ELISpot are plotted. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 ≥ 65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 ≥ 65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 ≥ 65 year olds). The right panel includes only participants with paired data available n=34 (n=19 18-50 year olds, n=8 51-64 year olds and n=7 ≥ 65 year olds), n=24 (n=10 18-50 year olds, n=7, 51-64 year olds and n=7 ≥ 65 year olds) and n=28 (n=14 18-50 year olds, n=5 51-64 year olds and n=9 ≥ 65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively.

B) Example gating strategy for flow cytometry assays.

C-D) Intracellular cytokine staining for IFN-g (purple) IL-2 (gray), TNF-a (blue) or any of the three cytokines (red) are plotted from samples collected at baseline or post-dose 2. The graphs include n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 ≥ 65 year olds), n=35 participants in the 1.0 mg dose group (n=19 18-50 year olds, n=10 51-64 year olds and n=10 ≥ 65 year olds) and n=36 participants in the 2.0 mg dose group (n=19 18-50 year olds, n=10 51-64 year olds and n=10 ≥ 65 year olds). Open symbols represent individual participants, the box extends from the 25th to the 75th percentile, line inside the box is the median, and the whiskers extend from the minimum to maximum values. The mean is denoted with a “+” sign. Wilcoxon signed-rank was used to assess significance versus baseline. The dose groups are represented by triangles (0.5 mg), circles (1.0 mg) and squares (2.0 mg).



C



D

